Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer(University of Pennsylvania), Shirish M. Gadgeel(The Barbara Ann Karmanos Cancer Institute), Hossein Borghaei(Fox Chase Cancer Center), Vassiliki A. Papadimitrakopoulou(The University of Texas MD Anderson Cancer Center), Amita Patnaik(South Texas Accelerated Research Therapeutics), Steven Powell, Ryan D. Gentzler(University of Virginia), Renato Martins(University of Washington), James Stevenson(Cleveland Clinic), Shadia I. Jalal(Indiana University School of Medicine), Amit Panwalkar(Fargo VA Health Care System), James Chih‐Hsin Yang(National Taiwan University Hospital), Matthew A. Gubens(University of California, San Francisco), Lecia V. Sequist(Harvard University), Mark M. Awad(Dana-Farber Cancer Institute), Joseph Fiore(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yang Ge(Merck & Co., Inc., Rahway, NJ, USA (United States)), Harry Raftopoulos(Merck & Co., Inc., Rahway, NJ, USA (United States)), Leena Gandhi(Dana-Farber Cancer Institute)
Cited by 1,389
Abstract
Related Papers
No related papers found
Powered by citation graph analysis